The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder

Journal of Psychiatric Research

Volumn 46, Issue 11, 2012, Pages 1406-1413

  Garlow, Steven J ^a   Dunlop, Boadie W ^a   Ninan, Philip T ^b   Nemeroff, Charles B ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Augmentation; Depression; Remission; Response; Triiodothyronine

Indexed keywords

LIOTHYRONINE; PLACEBO; SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MICTURITION; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEDATION; SIDE EFFECT; STOMACH DISCOMFORT; SWEATING; THORAX PAIN; TREATMENT RESPONSE; TREMOR; XEROSTOMIA;

EID: 84866911116     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.08.009     Document Type: Article

References (36)

1. Abraham G., Milev R., Lawson J.S. T3 augmentation of SSRI resistant depression. Journal of Affective Disorders 2006, 91:211-215.
2. Altshuler L., Bauer M., Frye M.A., Gitlin M.J., Mintz J., Szuba M.P., et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry 2001, 158(10):1617-1622.
3. Appelhof B.C., Brouwerr J.P., van Dyck R., Fliers E., Hoogendijk W.J.G., Huyser J., et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. Journal of Clinical Endocrinology & Metabolism 2004, 89:6271-6276.
4. Aronson R., Offman H., Joffe R., Naylor D. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Archives of General Psychiatry 1996, 53:842-848.
5. Bauer M., Forsthoff A., Baethge C., Adli M., Berghofer A., Dopfmer S., et al. Lithium augmentation therapy in refractory depression - update 2002. European Archives of Psychiatry and Clinical Neuroscience 2003, 253(3):132-139.
6. Blier P., Ward H.E., Tremblay P., Laberge L., Hebert C., Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. American Journal of Psychiatry 2010, 167:281-288.
7. Cooper-Kazaz R., Apter J.T., Cohen R., Karagichev L., Muhammed-Moussa S., Grupper D., et al. Combined treatment with sertraline and liothyronine in major depression. Archives of General Psychiatry 2007, 64:679-688.
8. Cooper-Kazaz R., van der Deure W.M., Medici M., Visser T.J., Alkelai A., Glaser B., et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. Journal of Affective Disorders 2009, 116:113-116.
9. Fabre L.F., Abuzzahab F.S., Amin M., Claghorn J.L., Mendels J., Petrie W.M., et al. Setraline safety and efficacy in major depression: a double-blind, fixed-dose comparison with placebo. Biological Psychiatry 1995, 38:592-602.
10. Fava M., Rush A.J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and proposal for a novel approach to improve practice. Psychotherapy and Psychosomatics 2006, 75(3):139-153.
11. Feldmesser-Reiss E.E. The application of triiodothyronine in the treatment of mental disorders. Journal of Nervous and Mental Disease 1958, 127:540-546.
12. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W., et al. Structured clinical interview for DSM-IV axis I disorders 1998, (SCID-I/P, v. 2.0, 8/98 revision), Biometrics Research Department, New York.
13. Flach F.F., Celian C.I., Rawson W.W., et al. Treatment of psychiatric disorders with triiodothyronine. American Journal of Psychiatry 1958, 114:841-842.
14. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Archives of General Psychiatry 1991, 48:851-855.
15. Clinical Global Impression (CGI). ECDEU assessment manual for psychopharmacology 1976, Department of Health, Education, and Welfare, Rockville, U.S. W. Guy (Ed.).
16. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960, 23:56-62.
17. Iosifescu D.V., Nierenberg A.A., Mischoulon D., Perlis R.H., Papkostas G.I., Ryan J.L., et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 2005, 66:1038-1042.
18. Keitner G.I., Garlow S.J., Ryan C.E., Ninan P.T., Solomon D.A., Nemeroff C.B., et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. Journal of Psychiatric Research 2009, 43(3):205-214.
19. Lydiard R.B., Stahl S.M., Hertzman M., Harrison W.M., et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. Journal of Clinical Psychiatry 1997, 58(11):484-491.
20. Maes M., Libbrecht I., van Hunsel F., Campens D., Meltzer H.Y., et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including these with treatment resistance. Journal of Clinical Psychopharmacology 1999, 19(2):177-182.
21. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979, 134:382-389.
22. Nierenberg A.A., Fava M., Trivedi M., Wisniewski S.R., Thase M.E., McGrath P.J., et al. Comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR D report. American Journal of Psychiatry 2006, 163:1519-1530.
23. Nierenberg A.A., Wright E.C. Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry 1999, 60(Suppl. l2):7-11.
24. Papkostas G.I., Cooper-Kazaz R., Appelhof B.C., Posternak M.A., Johnson D.P., Klibanski A., et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. International Clinical Psychopharmacology 2009, 24:19-25.
25. Papkostas G.I., Shelton R.C. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Current Psychiatry Reports 2008, 10(6):481-486.
26. Posternak M.A., Novak S., Stern R., Hennessey J., Joffe R., Prange A., et al. A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. International Journal of Neuropsychopharmacology 2007, 11:15-25.
27. Rush A.J., Kraemer H.C., Sackeim H.A., Fava M., Trivedi M., Frank E., et al. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 2006, 31:1841-1853.
28. Rush A.J., Trivedi M., Carmody T.J., Biggs M.M., Shores-Wilson K., Ibrahim H., et al. One- year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biological Psychiatry 2004, 56:46-53.
29. Rush A.J., Trivedi M., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. American Journal of Psychiatry 2011, 168:689-701.
30. Rush A.J., Trivedi M., SR, Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 2006, 354(12):1231-1242.
31. Seemuller F., Riedel M., Obermeier M., Bauer M., Adli M., Kronmuller K., et al. Outcomes of 1014 naturalistically treated inpatients with major depressive episode. European Neuropsychopharmacology 2010, 20(5):346-355.
32. Stewart J.W., McGrath P.J., Deliyannides D.A., Quitkin F.M. Does dual antidepressant therapy at initial treatment hasten and increase remission from depression. Journal of Psychiatric Practice 2009, 15(5):337-345.
33. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001, 178:234-241.
34. Trivedi M., Fava M., Wisniewski S.R., Thase M.E., Quitkin F.M., Warden D., et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 2006, 354(12):1243-1252.
35. Trivedi M., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. American Journal of Psychiatry 2006, 163:28-40.
36. Valenstein M., McCarthy J.F., Austin K.L., Greden J.F., Young E.A., Blow F.C. What happened to lithium? Antidepressant in clinical settings. American Journal of Psychiatry 2006, 163:1219-1225.